// App-Quantinova.ai

9046 : First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).

Researchers

Presenter

  • Vera Hirsh

Principal Investigators

  • Eng-Huat Tan

  • Ken O'Byrne

  • Li Zhang

  • Michael J. Boyer

  • Tony Mok

  • Ki Hyeong Lee

  • Shun Lu

  • Yuankai Shi

  • Sang-We Kim

  • Janessa J. Laskin

  • Dong-Wan Kim

  • Catherine Dubos Arvis

  • Karl Kolbeck

  • Martin H. Schuler

  • Dan Massey

  • Angela Maerten

  • Luis Paz-Ares

  • Keunchil Park

Medical Centers

  • Montreal University, Montreal, QC, Canada

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • National Cancer Centre Singapore, Singapore, Singapore

  • Princess Alexandra Hospital & Queensland University of Technology, Brisbane, Australia

  • Cancer Center Sun Yat Sen University, Guangzhou, China

  • Chris O'Brien Lifehouse, Camperdown, Australia

  • Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

  • Shanghai Renji Hospital, Shanghai, China

  • Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

  • BC Cancer Agency, Vancouver, BC, Canada

  • Centre Francois Baclesse, Caen, France

  • Karolinska University Hospital, Stockholm, Sweden

  • West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany

  • Boehringer Ingelheim Ltd, Bracknell Berkshire, United Kingdom

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

  • Hospital Universitario Doce de Octubre, Madrid, Spain

Locations

  • Canada

  • Taiwan

  • China

  • Singapore

  • Germany

  • Spain

  • United Kingdom

  • Australia

  • France

  • Sweden

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • gefitinib

  • Afatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01466660AE

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved